gsk2862277
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2013 (NCT01818024)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor receptor R1INHIBITOR
TNFRSF1A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2862277
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02221037 | Phase 2 | Apr 28, 2015 | GlaxoSmithKline |
| NCT01818024 | Phase 1 | Feb 22, 2013 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2013 |
1 organizations
Page 1 / 1